These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26335016)

  • 21. Current therapy of Parkinson's disease.
    Ajax T; Rodnitzky R; Dobson J
    Iowa Med; 1997 Feb; 87(2):71-3. PubMed ID: 9055504
    [No Abstract]   [Full Text] [Related]  

  • 22. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rasagiline for motor complications in Parkinson's disease.
    Clarke CE
    Lancet; 2005 Mar 12-18; 365(9463):914-6. PubMed ID: 15766976
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
    Viallet F; Pitel S; Lancrenon S; Blin O
    Curr Med Res Opin; 2013 Jan; 29(1):23-31. PubMed ID: 23176073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rasagiline-induced spontaneous ejaculation.
    Chuang RS; Lang AE
    Mov Disord; 2009 Oct; 24(14):2160-1. PubMed ID: 19735087
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety of rasagiline in elderly patients with Parkinson disease.
    Goetz CG; Schwid SR; Eberly SW; Oakes D; Shoulson I;
    Neurology; 2006 May; 66(9):1427-9. PubMed ID: 16682679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram].
    Bandrés Liso AC; Toyas Miazza C
    Farm Hosp; 2009; 33(3):173-5. PubMed ID: 19712602
    [No Abstract]   [Full Text] [Related]  

  • 29. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
    Wilson L; Sheehan J; Thorpe M
    Ir Med J; 2013 Jan; 106(1):24-5. PubMed ID: 23472375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients.
    Brusa L; Musco S; Bernardi G; Iani C; Pierantozzi M; Stanzione P; Stefani A; Finazzi Agro' E
    Parkinsonism Relat Disord; 2014 Aug; 20(8):931-2. PubMed ID: 24861661
    [No Abstract]   [Full Text] [Related]  

  • 31. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
    Wilson RE; Seeberger LC; Silver D; Griffith A; Conner JB; Salzman PM;
    Neurologist; 2011 Nov; 17(6):318-24. PubMed ID: 22045282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    Jost WH; Friede M; Schnitker J
    Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
    [No Abstract]   [Full Text] [Related]  

  • 34. Levodopa-associated hemifacial dystonia.
    Mark MH; Sage JI
    Mov Disord; 1991; 6(4):383. PubMed ID: 1758464
    [No Abstract]   [Full Text] [Related]  

  • 35. Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia.
    Frakey LL; Friedman JH
    J Neuropsychiatry Clin Neurosci; 2017; 29(1):22-25. PubMed ID: 27829318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Square-wave action dystonia in Parkinson's disease.
    van den Munckhof P; Lenz FA; Chase TN
    Mov Disord; 1998 Mar; 13(2):354-6. PubMed ID: 9539355
    [No Abstract]   [Full Text] [Related]  

  • 37. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypersexuality induced by rasagiline in monotherapy in Parkinson's disease.
    Simonet C; Fernández B; Cerdán DM; Duarte J
    Neurol Sci; 2016 Nov; 37(11):1889-1890. PubMed ID: 27401808
    [No Abstract]   [Full Text] [Related]  

  • 39. Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
    Zagmutt FJ; Tarrants ML
    Int J Neurosci; 2012 Jul; 122(7):345-53. PubMed ID: 22304415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
    Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J
    Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.